Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 9 staff and has a trailing 12-month revenue of around USD$334,000.
Since the stock market crash in March caused by coronavirus, VistaGen Therapeutics's share price has had significant positive movement.
Its last market close was USD$0.72, which is 3.22% up on its pre-crash value of USD$0.6968 and 140.00% up on the lowest point reached during the March crash when the shares fell as low as USD$0.3.
If you had bought USD$1,000 worth of VistaGen Therapeutics shares at the start of February 2020, those shares would have been worth USD$461.50 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$946.12.
|Latest market close||USD$0.72|
|52-week range||USD$0.3 - USD$1.06|
|50-day moving average||USD$0.7319|
|200-day moving average||USD$0.6485|
|Wall St. target price||USD$4.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.829|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||0.72|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-67.41%|
|Return on equity TTM||-293.91%|
|Market capitalisation||USD$59 million|
TTM: trailing 12 months
There are currently 2.9 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 9.2% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.
VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 695968.34532374). VistaGen Therapeutics's SIR currently stands at 4.17. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 4170 shares are currently held short.
However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0428% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.
Find out more about how you can short VistaGen Therapeutics stock.
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
VistaGen Therapeutics's shares were split on a 1:20 basis on 14 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.3 up to $1.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.4515. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.